Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy

Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy

Endocrine therapy is considered as an effective strategy for estrogen and progestogen receptor (ER and PR)-positive breast cancer (BRCA) patients, whereas resistance to these agents is the major cause of BRCA mortality in women. Immune checkpoint receptor (ICR) blockade is another approach to treat...

Full description

Bibliographic Details
Main Authors: Peng Li, Wenhui Yuan, Ruan Wu, Chuqian Zeng, Ke Li, Ligong Lu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
androgens
androgen receptor
breast cancer
immune checkpoint receptors
γδ T cells
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.917400/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.917400/full

Similar Items